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Abstract
Background: Multiple system atrophy (MSA) is a rare neurodegenerative movement disorder characterized by a rapidly progressive course. The clinical
presentation can include autonomic failure, parkinsonism, and cerebellar signs. Differentiation from Parkinson’s disease (PD) is difficult if there is levodopa-
responsive parkinsonism, rest tremor, lack of cerebellar ataxia, or mild/delayed autonomic failure. Little is known about tremor prevalence and features in MSA.
Methods: We performed a PubMed search to collect the literature on tremor in MSA and considered reports published between 1900 and 2013.
Results: Tremor is a common feature among MSA patients. Up to 80% of MSA patients show tremor, and patients with the parkinsonian variant of MSA are
more commonly affected. Postural tremor has been documented in about half of the MSA population and is frequently referred to as jerky postural tremor with
evidence of minipolymyoclonus on neurophysiological examination. Resting tremor has been reported in about one-third of patients but, in contrast to PD, only
10% show typical parkinsonian ‘‘pill-rolling’’ rest tremor. Some patients exhibit intention tremor associated with cerebellar dysmetria. In general, MSA patients can
have more than one tremor type owing to a complex neuropathology that includes both the basal ganglia and pontocerebellar circuits.
Discussion: Tremor is not rare in MSA and might be underrecognized. Rest, postural, action and intention tremor can all be present, with jerky tremulous
movements of the outstretched hands being the most characteristic. However, reviewing the data on tremor in MSA suggests that not every shaky movement
satisfies tremor criteria; therefore, further studies are needed.
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Introduction
Multiple system atrophy (MSA) is a fatal, adult-onset, neurodegen-
erative disease with rapid progression and limited symptomatic
treatment options. Clinical features include parkinsonism and
cerebellar and autonomic signs and symptoms in various combina-
tions. Two major motor variants are distinguished according to the
predominant motor presentation: MSA parkinsonian variant (MSA-P)
and MSA cerebellar variant (MSA-C). In Europe and North America,
the distribution is in favor of the MSA-P variant, whereas MSA-C is
more prevalent in Japan. Neuropathological correlates of MSA-P
and MSA-C are striatonigral degeneration and olivopontocerebellar
atrophy, respectively.
The clinical presentations of both Parkinson’s disease (PD) and
MSA include akinesia and rigidity associated with tremor. The
cardinal feature of PD is rest tremor, which is found in more than 70%
of patients at disease onset.1 The classic parkinsonian rest tremor is
defined as rest tremor or rest and postural/kinetic tremor of the
same frequency.2 Usually, parkinsonian rest tremor mostly affects a
unilateral upper extremity, at least initially, and shows a frequency of
4–6 Hz, whereas the upper frequency can reach up to 9 Hz, especially
in early stages of the disease.2 This kind of rest tremor has a
characteristic appearance, with an alternating activation of agonist and
antagonist. Typically, the thumb and forefingers move back and forth
as if manipulating small objects in the hand; the term ‘‘pill-rolling’’ rest
tremor is commonly used when referring to the classic parkinsonian
tremor. In PD, rest tremor can also be accompanied by postural/
kinetic tremor of a different frequency, and some patients even exhibit
isolated postural and kinetic tremors.3
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The classification of tremor is not as clear in MSA, although
postural tremor appears to be more common than rest tremor.4–9
Clinical studies have shown that tremor is observed in about one-third
of patients during rest and about half of patients during posture, with
greater tremor rates in the MSA-P variant compared with the MSA-C
variant.4,8,10,11 The presence of either rest or postural tremor in
association with parkinsonism can cause diagnostic confusion.
However, there is evidence that tremor presents differently in MSA
versus PD: atypical or jerky components have been reported, and the
classic parkinsonian (pill-rolling) rest tremor is only present in a
minority of patients (,10%).4,6,12,13 Thus, pill-rolling rest tremor
supports a diagnosis of PD. Intention tremor points away from PD but
is typical in MSA, especially MSA-C (up to 45% of patients).8 Tremor
of the legs, head, chin, lips, and tongue can be found in PD but are all
uncommon in MSA.14
To date, little has been written about tremor rates and character-
istics in MSA, and few attempts have been made to formulate an MSA
tremor classification. Nevertheless, the revised consensus criteria for
the diagnosis of MSA include tremor, not further classified, as a feature
of possible or probable MSA if occurring in the context of
bradykinesia, rigidity, or postural instability.15 The classic pill-rolling
rest tremor is referred to as a nonsupportive feature, whereas jerky
myoclonic postural/action tremor is supportive for the diagnosis of
MSA.15
In this review, we systemically analyze the available evidence on
tremor in MSA, highlighting features that might improve the
differential diagnosis, particularly with regard to PD.
Methods
Data for this review were identified by searching PubMed with the
terms ‘‘multiple system atrophy,’’ ‘‘Parkinson’s disease,’’ ‘‘parkinson-
ism,’’ ‘‘tremor,’’ ‘‘rest tremor,’’ ‘‘postural tremor,’’ ‘‘action tremor,’’
‘‘intention tremor,’’ ‘‘myoclonus,’’ ‘‘jerky tremor,’’ ‘‘clinical,’’ ‘‘clin-
icopathological,’’ ‘‘imaging,’’ and ‘‘neurophysiology.’’ References from
1900 to 2013 were considered, including case reports and natural
history, clinical, clinicopathological, neurophysiological, and imaging
studies, summarizing rates of occurrence, site, and tremor and subtype
characteristics in MSA patients.
The classification of tremor can be made according to the consensus
statement of the Movement Disorder Society, depending on the
circumstances under which it occurs.2
Results
Ever since documentation of the first MSA cases, tremor has been
considered a clinical feature of the disease. Tremor in MSA, formerly
known as striatonigral degeneration, olivopontocerebellar atrophy, or
Shy–Drager syndrome, was first mentioned in one of two patients with
olivopontocerebellar atrophy in 1900.16 In the following case reports
by Langston in 1936 and Young in 1944, tremor was not explicitly
stated as a distinct feature of parkinsonism.17,18 In 1960, Shy and
Drager described two patients with orthostatic hypotension and
additional parkinsonian features, both of whom showed rest tremor of
the hand, and one case also upon movement.19 In 1961, Adams and
associates reported three striatonigral degeneration patients with an
akinetic-rigid syndrome with rest tremor of a frequency of 4–5 Hz.20
In addition, ataxia and speech disturbances were accompanied by
intention tremor in one patient. In 1973, Aminoff and coworkers
evaluated the dopaminergic response of five patients with Shy–Drager
syndrome with parkinsonism including tremor; one patient worsened
and the other four experienced no improvement.21 In 1989, Quinn
contributed substantially to the understanding of MSA, stating that
‘‘symmetrical onset and absence of classical resting tremor,’’ which had
previously been regarded as features distinguishing MSA from PD,
may not be as helpful in making the differential diagnosis because
marked and persistent asymmetry and the presence of classical rest
tremor had all been reported in pathologically proven MSA.22 Instead,
Quinn said that irregular jerky postural tremor and myoclonus might
represent ‘‘red flags’’ (i.e., clinical features raising doubt about a
diagnosis of PD), as they appear to be more common in MSA than PD.
Several clinical and clinicopathological studies in MSA have
demonstrated that tremor is not rare in this condition, reporting an
overall occurrence of up to 80% (Table 1) .4,6,8,10,11,13,23 Comparisons
of tremor occurrence in the motor subtypes of MSA have clearly
shown that tremor is more common in MSA-P compared with MSA-C
(31–83% for MSA-P and 12–48% for MSA-C; Table 2).4,8,10,11
Rest tremor
Rest tremor is common in MSA, with a frequency ranging from
25% to 43% and is more common in patients with MSA-P (32–44%)
compared with MSA-C (17–26%; Tables 1 and 2).4–10,13,24–26
In Europe, the first comprehensive clinical study on MSA, including
tremor evaluation, was performed by Wenning and associates in
1994.4 This study showed that among 100 probable MSA patients (82
MSA-P and 18 MSA-C), 29% had rest tremor, including 32% of the
MSA-P cohort and 17% of the MSA-C cohort. Classic parkinsonian
rest tremor with pill-rolling appearance was observed in only 9% of the
entire MSA population (10% of MSA-P and 6% of MSA-C patients).4
Further clinical investigations by Wu¨llner and colleagues, as well as
Rodriguez and coworkers, have reported a rest tremor frequency of
25% in both MSA-P and MSA-C.24,25 Tison and associates reported
typical rest tremor rates of 12%, whereas atypical rest tremor (defined
as fast, irregular, or myoclonic) was documented in up to 36% of MSA
patients (for further details, see section ‘‘Evolution of MSA tremor’’).6
The largest MSA cohort investigation to date utilized the European
MSA (EMSA) registry and included 437 patients (72% with a diagnosis
of probable MSA, 28% classified as possible MSA; 68% MSA-P and
32% MSA-C) (www.emsa-sg.org), reported a rest tremor frequency of
33%; the presence of classic pill-rolling tremor was not assessed.5 The
most recent data are provided by an EMSA natural history study
conducted by Wenning and associates, which followed 141 MSA
patients (87 MSA-P and 54 MSA-C) for 2 years after symptom onset.9
In this study, the rest tremor rate ranged from 35% to 43% of MSA
patients, with MSA-P patients more commonly affected than those
with MSA-C.
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Clinicopathological correlations by Wenning and associates in 1995
and 1997, including 35 and 203 pathologically confirmed MSA cases,
respectively, support the clinical data; they reported a rest tremor
prevalence of 34–39%.10,13 Only 8–11% of cases could be classified as
classic pill-rolling rest tremor. A clinicopathological study from
Australia showed comparable results: despite a rather small study
population (n512), they reported that 33% of MSA patients had rest
tremor.26
In the United States, the North American MSA Study Group
(NAMSA-SG) cohort, consisting of 84 probable MSA patients clinically
dominated by parkinsonian features, 39% of patients exhibited rest
tremor.7 Contrasting results were reported for a clinicopathological
investigation of 26 pathologically proven MSA patients (18 MSA-P and
8 MSA-C), in which only 10% of patients showed rest tremor.27
Explanations for these different findings might be the small numbers of
patients included or misdiagnoses in prospective studies.
A rest tremor evaluation in a Japanese MSA cohort (18 MSA-P and
31 MSA-C) paralleled the European results, detecting rest tremor in
44% of MSA-P and 26% of MSA-C patients.8 One further study
reported lower tremor rates.11
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Table 1. Tremor in MSA




Clinical, prospective, n5100, 82% MSA-P,
18% MSA-C
29 (9 pill-rolling) P: 47 (20 jerky)
A: 20
15 66 4
Clinical, prospective, n524, 100% MSA-C 25 NR NR NR 24
Clinicopathological, n535, 86% MSA-P,
14% MSA-C
34 (11 pill-rolling) P: 29
A: 9
11 80 13
Clinicopathological, n5203, 60% MSA-P,
28% MSA-C, 12% mixed




Clinical, prospective, n511, 100% MSA-P 9 pill-rolling NR NR NR 29







Clinical, prospective, NAMSA-SG, n584,
MSA-P.MSA-C
39 P: 64 NR NR 7
Clinical, retrospective, n549, 63% MSA-C,
37% MSA-P
33 NR 39 61 8
Clinical, retrospective, German Parkinson




Clinical, prospective, red-flag study, EMSA-
SG, n557, 100% MSA-P
NR P: 47 jerky NR NR 30
Clinical, retrospective, EMSA registry,
n5437, 68% MSA-P and 32% MSA-C
33 P: 54 NR NR 5
Clinicopathological, n543, 12 MSA, 15
PSP, 8 PD and 8 healthy controls
33 NR NR NR 26
Clinical, prospective, n5141, 62% MSA-P,
38% MSA-C
35–43% 56–67% NR NR 9
*At latest follow-up.
Abbreviations: A, action tremor; EMSA-SG, European Multiple System Atrophy Study Group; MSA, multiple system atrophy; MSA-C, multiple system atrophy
cerebellar variant; MSA-P, multiple system atrophy parkinsonian variant; NAMSA-SG, North American Multiple System Atrophy Study Group; NR, not reported; P,
postural tremor; PD, Parkinson’s disease; PSP, progressive supranuclear palsy.
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In summary, rest tremor is present in about one-third of MSA
patients, particularly in those with the parkinsonian subtype. It is rarely
the pill-rolling type, but this can create a significant diagnostic
dilemma.
Postural tremor and myoclonus
In general, postural tremor is regarded the most common tremor
variant among MSA patients. Its frequency ranges from 28% to 67%,
and it is more commonly observed in MSA-P than MSA-C patients
(47–55% versus 22%, respectively; Tables 1 and 2). 4,5–10,13,25,28,30
In contrast to postural tremor in PD, which has been well defined by
the Movement Disorder Society,2 there have been few attempts to
define this tremor in MSA.
A clinical evaluation by Wenning and colleagues in 1994 revealed
postural tremor frequency in 47% out of 100 probable MSA patients,
including 52% of MSA-P and 22% of MSA-C patients. A ‘‘jerky
irregular tremor’’ was documented in 20% of patients dominated
by MSA-P. Moreover, stimulus-sensitive myoclonus of the upper
extremity was seen in 31% of patients, more commonly in MSA-P
than MSA-C (45% versus 33%).4 In the same year, Rodriguez and his
group demonstrated that all but one of 24 MSA-C patients showed
reflex myoclonus of the hands/arms on electrophysiological investi-
gation. Unfortunately, clinical evaluation of postural tremor was not
documented.24 Shortly after, in 1995, Gouider-Khouja and collea-
gues performed a comparative study between 18 PD and 18 MSA-P
patients.28 They reported jerky postural tremor in 55% of MSA-P
patients, of whom 16.6% showed stimulus-sensitive myoclonus
clinically. They concluded that, if present, postural tremor is highly
suggestive of MSA.28 In a subsequent investigation conducted in the
same year, postural tremor was documented in 29% of the total
cohort of 35 pathologically confirmed MSA patients; again, the
cohort was dominated by the MSA-P presentation (30 MSA-P and
five MSA-C patients); clinical myoclonus was also reported in 29% of
patients.13
In 2000, clinical and electrophysiological investigations by Salazar
and colleagues revealed that all but 2 of their 11 MSA-P patients who
presented with abnormal, small-amplitude, nonrhythmic movements
of the fingers or hands when holding a posture or at the beginning of
an action showed evidence of ‘‘minipolymyoclonus.’’29
In 2008, assessment of clinically useful red flags pointing toward a
diagnosis of MSA showed that jerky tremor, defined as ‘‘irregular
postural or action tremor of the hands and/or fingers with stimulus-
sensitive myoclonus,’’ is a feature that appears more often in MSA-P
than in PD (47.4% versus 5.9% of patients, respectively) and therefore
serves as a supporting feature of MSA (94.1% specificity).30 However,
subsequent analyses of the EMSA registry reported in 2010 made no
mention of ‘‘jerky tremor’’; instead, a postural tremor rate of 54%
(68.2% MSA-P and 31.8% MSA-C) was reported.5
A recent clinical evaluation of 141 MSA patients (87 MSA-P and 54
MSA-C) revealed postural tremor rates ranging from 56% to 67% of
MSA patients (2-year follow-up after symptom onset).9
In the United States, the NAMSA-SG reported a postural tremor
frequency of 64% in 84 MSA patients, with parkinsonism being the
predominant motor feature.7
Results of a Japanese clinical study with 142 probable MSA patients
(119 MSA-C and 23 MSA-P) showed a contrast with the high
frequency of postural tremor in western hemisphere studies. Within
these analyses, postural tremor was only assessed in combination with
action or rest tremor. The combination of rest and postural tremor
resulted in a frequency of 8.7% in MSA-P patients and 1.7% in MSA-
C patients. The combination of action and postural tremor accounted
for 10.1% of MSA-C and 8.7% of MSA-P patients.11 The reasons for
this discrepancy remain unresolved.
Taken together, postural tremor appears to be the most common
tremor subtype in MSA, especially in MSA-P. Moreover, a jerky/
irregular appearance has been linked to postural MSA tremor, and
there is electrophysiological evidence suggesting that these irregular
and small-amplitude involuntary movements of the hands and/or
fingers correspond to myoclonus rather than tremor.4,9,29,30
Furthermore, stimulus-sensitive myoclonus (with or without tremor)
of the upper extremity is not rare (found in 16.6–95% of MSA
patients).4,24,28,30 The clinical differentiation between jerky postural
tremor and myoclonus, especially if both are present, has not always
been made, and further studies including a greater number of MSA
patients are needed to clarify and characterize tremulous versus
myoclonic movements, respectively.
Intention tremor
In MSA-C, the typical tremor variant is intention tremor paralleling
cerebellar pathology. Wenning and colleagues have demonstrated that
intention tremor is present in 15% of all MSA patients.4 Looking
specifically at MSA-C patients, intention tremor was documented in one-
third of patients, whereas intention tremor was found in only 11% of the
MSA-P population.4 Assessment of pathologically proven MSA patients
by the same group revealed intention tremor frequencies of 11–24%.13
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Any 31–83 12–48 4, 8, 10, 11




Jerky/postural 47–55 22 4, 28, 30
Action 22 11 4
Intention 11–28 33–45 4, 8
Abbreviations: MSA-C, multiple system atrophy cerebellar variant;
MSA-P, multiple system atrophy parkinsonian variant.
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Longitudinal observations have demonstrated that intention tremor
may be present at the initial visit of a patient with MSA (2%) but more
characteristically develops throughout the disease course (32%),
reflecting the cerebellar dysfunction that develops in more than half
of MSA-P and MSA-C patients with disease progression (see section
‘‘Evolution of MSA tremor’’).6
In line with the European findings, a Japanese study including 31
MSA-C patients and 18 MSA-P patients showed intention tremor
rates of 45% and 28%, respectively.8 Neither of the American studies
on MSA evaluated intention tremor.7,27
In summary, intention tremor is supportive of a diagnosis of MSA
and in a differential diagnosis of PD, intention tremor is indicative of
MSA. It appears more commonly in MSA-C patients, although its
presence does not exclude a diagnosis of MSA-P. Intention tremor can
be present at symptom onset but more typically develops throughout
the disease course. Because of this tendency to develop at later disease
stages, intention tremor might not be helpful as a diagnostic marker;
however, if present, it is very characteristic of MSA.
Evolution of MSA tremor
Three longitudinal studies have specifically looked at tremor
evolution in MSA.6,9,31 The first was performed by Tison and
colleagues, who followed 50 MSA patients (15 MSA-C and 35 MSA-P)
and 50 PD patients for 4.35 years after disease onset.6 The analyses
found that limb tremor as a presenting symptom was 10 times more
common in PD than in MSA. In addition, classical pill-rolling
parkinsonian tremor was less frequent in MSA than in PD (12% versus
68%, respectively, at initial visit; and 12% versus 74% at follow-up).
However, atypical tremor at rest, defined as fast, irregular, or
myoclonic, was significantly more common in MSA than PD patients
at both the initial visit (22% versus 4%, respectively) and the follow-up
examination (36% versus 4%). Postural tremor was significantly more
frequent at the initial visit in MSA compared with PD patients (28%
versus 6%), but there was no significant difference between the two
cohorts at follow-up (50% versus 52%). Action tremor was significantly
more common at the initial visit in MSA patients (14% versus 6%) and
was even more significant at the follow-up examination (38% versus
16%). Intention tremor was rare in MSA patients at the initial visit
(documented in only one patient), whereas 16 patients (32%) exhibited
intention tremor at the follow-up visit, reflecting the cerebellar
dysfunction that develops in more than half of both MSA-P and
MSA-C patients throughout the course of the disease.6 Taken
together, this very detailed study demonstrated that limb tremor is
more frequent in PD than in MSA as an initial symptom. While MSA
patients do exhibit rest tremor, classic parkinsonian rest tremor is
uncommon. Furthermore, postural and action tremor are more
frequent in MSA at the initial visit, with increasing frequencies during
follow-up in both disorders. Action and intention tremor also
discriminate between MSA and PD (Table 3).6
Interestingly, an investigation of progression rates of parkinsonism in
MSA-P patients (mean 11.8 months following first visit) by Seppi and
colleagues, including validated rating scales (Unified Parkinson’s
Disease Rating Scale III, Schwab and England Scale, and Hoehn
and Yahr Scale), showed that there was a significant decline in motor
function at the follow-up visit compared with the initial visit, except for
the tremor item, which did not progress in the same pattern as akinesia
and rigidity.31
A very recent and detailed longitudinal observation study reported
on the progression of tremor subtypes in MSA over 2 years. Both rest
and postural tremor were documented, with no significant change in
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Table 3. Evolution of MSA Tremor (Modified According to Tison et al 20026)
Tremor Type Initial Visit (%) Follow-up Visit (%)*
MSA PD MSA PD
Any** 50 82 62 84
Unilateral 26 56 24 20
Asymmetrical 16 12 12 40
Classic pill-rolling 12 68 12 74
Atypical rest+ 22 4 36 4
Postural 28 6 50 52
Action 14 6 38 16
Intention 2 0 32 12
*Mean follow-up time was 5.5 years after initial presentation.
**Including upper and lower limbs in terms of unilateral and asymmetric appearance and including postural, rest, action, and intention tremor.
+Defined as fast, irregular, or myoclonic.
Abbreviations: MSA, multiple system atrophy; PD, Parkinson’s disease.
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either tremor variant subtype in terms of occurrence over a 2-year
follow-up period. Rest tremor rates developed as follows: 35.5% at
baseline examination, 43.6% at 6 months, 34.5% at 12 months, 40.8%
at 18 months, and 41.9% at 24 months. Similarly, postural tremor
showed the following course: 56% at baseline, 63.8% at 6 months,
66.7% at 12 months, 65.3% at 18 months, and 62.8% at 24 months.9
These two clinical studies indicate that tremor severity in MSA
patients, as well as the occurrence of tremor, do not change
throughout the observed time course (1 year in the analyses of Seppi
et al and 2 years in the study of Wenning et al).9,31 However, according
to the study by Tison and colleagues, disease duration might have an
impact on tremor rates, with a tendency for rates to increase for all
tremor subtypes (5-year follow-up).6
Tremor correlates in MSA
Neurophysiology. Accelerometer recordings allow evaluation of
abnormal movement and differentiation of rhythmic tremor from
arrhythmic components. Fourier analysis of the frequency spectra of
these accelerometric recordings differentiates tremor from other
movement disorders that can seem rhythmic upon initial inspection.
Patients with MSA can display a ‘‘jerky/irregular’’ tremor and
stimulus-sensitive myoclonus of the hands and fingers. Neuro-
physiological investigations have demonstrated that jerky postural
tremor in MSA consists of small-amplitude irregular oscillations with
no predominant peak in the fast Fourier frequency spectrum analyses
as found in PD, and it has therefore been proposed that these
movements are more compatible with a diagnosis of myoclonus rather
than tremor. The term ‘‘minipolymyoclonus’’ was introduced to
capture the cortical characteristics of jerky postural tremor in
MSA.10,24,32
Neuroimaging. Several imaging modalities, including computed
tomography (CT), magnetic resonance imaging (MRI) using diffu-
sion-weighted imaging and voxel-based morphometry, fludeoxyglu-
cose positron emission tomography (FDG-PET), iodine-123-(1beta-
carbomethyoxy-3beta-[4-iodophenyl]tropane) single-photon emission
computed tomography (beta-CIT-SPECT), and iodobenzomide
(IBZM)-SPECT have been successfully investigated as tools to
distinguish MSA from PD.33,34 Significant clinical correlations have
been demonstrated between cerebellar ataxia and infratentorial
abnormalities, including volume loss of the cerebellum, mesencepha-
lon, and pons, which had previously been demonstrated in a
clinicopathological study by Wenning and colleagues.10,35–37
There are controversial data regarding correlations between
putaminal abnormalities and parkinsonism. Schrag and associates did
not find an association between putaminal atrophy and parkinsonism,38
whereas Wakai and colleagues found a correlation between putaminal
atrophy and parkinsonism but not with substantia nigra narrowing.12
Therefore, Wakai and coworkers postulated that putamen volume loss is
associated with the clinical manifestation of parkinsonism.
To our knowledge, no imaging studies have specifically correlated
tremor and brain imaging abnormalities in MSA. In contrast, it is well
established that rest tremor in PD does not correlate with dopamine-
transporter imaging.38,39
Neuropathology. Detailed brain regional analyses performed by
Wenning and colleagues that investigated the degree of cell loss and
gliosis in the substantia nigra, putamen, caudate nucleus, inferior
olives, pons, Purkinje cells, dentate nucleus, intermediolateral cell
column, anterior horn cells, and spinal cord pyramidal tract failed to
show any correlation between cell loss and the presence of rest,
postural, and intention tremor in MSA.10 However, the retrospective
study design and the limited data quality of some instances likely
reduced the power of the study to detect tremor correlates. Another
clinicopathological study by Song and colleagues that assessed the
severity of regional atrophy, cell loss, and lesion densities between PD,
progressive supranuclear palsy, and MSA patients demonstrated that
clinical features including rest tremor correlated with tissue loss and
the severity of inclusion pathologies.26 In particular, they found an
association of rest tremor plus resistance to L-Dopa (L-3,4-dihydrox-
yphenylanine) treatment and greater globus pallidus atrophy, and
therefore postulated that preservation of the globus pallidus is crucial
for the generation of these features.
Therapy
Pharmacological therapy. Tremor in MSA is not a major therapeutic
target; akinesia-rigidity and dysautonomia are the most disabling
symptoms. Even so, there have been very few randomized controlled
trials in MSA as compared with PD.
Almost 40% of MSA patients respond to relative high doses of
L-Dopa (up to 1,000 mg/day) in the early stages of disease.4,5,9,39,40
However, the beneficial effects disappear after a few years, and
disabling dyskinesias occur in half of patients. Dopamine agonists
represent second-line drugs that can be used if side effects, such as
orthostatic hypotension and psychiatric symptoms, are tolerated.
About 10% of MSA patients have a good initial response to
bromocriptine and lisuride dopamine agonists.41,42 Other dopamine
agonists can also exert initial beneficial effects, although no controlled
trials have been performed. However, L-Dopa-responsive MSA
patients show a more pronounced benefit regarding akinesia and
rigidity compared with rest or postural tremor, which is comparable
with PD. Dopaminergic drugs have no effect on cerebellar tremor.
No benefits on parkinsonian features, including tremor, have been
reported with anticholinergics, which are commonly used in patients
with MSA to treat hypersalivation.
Three studies on a small number of MSA patients have shown that
amantadine improves parkinsonian symptoms, including tremor, in a
few patients.13,43,44 A beneficial effect was noted on movement
initiation and completion in patients with olivopontocerebellar
atrophy; there are no reports on other cerebellar symptoms, including
tremor.45
Despite the lack of randomized studies, some beneficial effect can be
expected on predominant postural tremor with nonselective beta-
blockers, such as propranolol.
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A possible benefit can also be seen with clonazepam for MSA
patients with jerky action or intentional tremor. There are no reports
on the use of botulinum toxin for MSA-associated tremor; however,
focal limb dystonia with contractures might improve.44
Surgical therapy. Medial pallidotomy failed to improve symptoms in
patients with striatonigral degeneration. Bilateral subthalamic stimula-
tion was reported to improve parkinsonism in four patients with MSA-
P, with the main benefits observed for rigidity and parkinsonism.46
However, other authors have reported deleterious effects of deep brain
stimulation.46–52
At present, surgical therapy is not considered an effective
therapeutic tool in the routine management of patients with MSA.
Discussion
This review of the published data on tremor in MSA, including
case reports and clinical, clinicopathological, neurophysiological, and
imaging studies, demonstrates that postural tremor is the most
commonly reported tremor type in MSA. It is documented in more
than half of patients at some point, followed by rest and intention
tremor, depending on the motor subtype of MSA and the disease
stage.4–7 Generally, patients with MSA-P are more frequently affected
by tremor than those with MSA-C.2,4,8,10 Jerky/irregular involuntary
movements, predominantly of the hands and fingers, are characteristic
when MSA patients are maintaining a posture. Considering that the
definition of tremor requires the presence of rhythmic, oscillatory,
involuntary movements, the term ‘‘jerky/irregular tremor’’ does not
satisfy these criteria; therefore, on electrophysiological grounds, the
term ‘‘minipolymyoclonus’’ might be more appropriate. In fact,
myoclonus, reported independently of postural tremor, is not rare in
MSA, and these tremor-like movements might be confused with
tremor in a clinical setting. To date, the classic parkinsonian rest
tremor with pill-rolling appearance has been considered to point
toward PD and away from atypical parkinsonism, including MSA.
However, it has been demonstrated that typical parkinsonian rest
tremor can also occur in patients with postmortem-proven MSA.10,13
Therefore, the occurrence of rest tremor can be a cause of diagnostic
failure in patients with additional symptoms suggestive of MSA.
Moreover, similar to postural tremor, rest tremor in MSA can be
atypical, with irregularity or myoclonic elements. Intention tremor as a
typical feature of cerebellar involvement is also characteristic of MSA
and more common in MSA-C, although it can also emerge in patients
with MSA-P. Typically, patients with MSA can exhibit more than one
kind of tremor owing to the complex neuropathology that includes
both the basal ganglia and pontocerebellar circuits.
Therapeutic approaches in patients with MSA mainly target
akinesia and rigidity. In general, tremor receives less attention in
these patients, and treatment options are very limited because of the
low response rate to L-Dopa and other dopaminergic substances.
Postural and action tremor, if severe and interfering with goal-directed
movements, might respond to benzodiazepines, such as clonazepam,
although no reports have been published on this topic. Intention
tremor is refractory to drug treatment, similar to in other etiologies
causing intention tremor, such as multiple sclerosis.47
In summary, tremor is not rare in MSA. However, the documenta-
tion of this condition is not standardized, and there is a lack of detailed
characterization of tremor in MSA despite its high prevalence among
MSA patients. Clearly, not every shaky movement is a tremor, and
distal myoclonic jerks in MSA patients might masquerade tremor more
commonly than previously thought. Nevertheless, these atypical
characteristics of tremulous movements upon rest and posture in
MSA can help to differentiate between PD and MSA. Further studies
are needed to address the multifaceted nature of tremor in MSA.
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Appendix: Assessment of Tremor in MSA According to
the Unified Multiple System Atrophy Rating Scale48
In the clinic, tremor in MSA patients is evaluated with the motor
part of the Unified MSA Rating Scale (UMSARS). Both rest and
action tremor are considered. Rest tremor is scored as follows: 0,
absent; 1, slight and infrequently present; 2, mild in amplitude and
persistent, moderate in amplitude but only intermittently present; 3,
moderate in amplitude and present most of the time; and 4, marked
in amplitude and present most of the time. Action tremor is evaluated
with respect to postural components, including examination of the
patient with outstretched arms (A) and intention components,
including examination of tremor on finger pointing (B). The maximal
tremor severity is scored on both tasks, and which limb is more
affected is documented. The scoring is as follows: 0, absent; 1, slight
tremor of small amplitude (A), no interference with finger pointing
(B); 2, moderate amplitude (A), some interference with finger pointing
(B); 3, marked amplitude (A), marked interference with finger
pointing (B); and 4, severe amplitude (A), finger pointing impossible
(B).
Jerky, myoclonic postural/action tremor is referred to as a
supporting feature in diagnosing MSA, whereas the classic pill-rolling
rest tremor is a nonsupporting feature.
Documentation of tremor
At the first visit, a handwriting sample can be taken from the patient
in case of action tremor. During follow-up, in addition to the clinical
examination including the UMSARS, drawing of the Archimedes
spiral and a second handwriting sample can be recorded to evaluate
disease progression and response to therapy, respectively.
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